CARBOGEN AMCIS' SHANGHAI SITE
CARBOGEN AMCIS announces successful ANVISA audit of its facility in China
March 19, 2024 13:58 ET | CARBOGEN AMCIS INNOVATIONS AG
CARBOGEN AMCIS announces successful completion of its first Brazilian Regulatory Authority Agency (ANVISA) routine inspection of its Shanghai facility
Logo DIPHARMA.jpg
Dipharma Receives the 2nd GMP Certification from Brazilian ANVISA
October 26, 2023 03:59 ET | Dipharma Francis S.r.l
MILAN, Italy, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Dipharma Francis S.r.l. (Dipharma), a leading Contract Development and Manufacturing Organization (CDMO) and a global manufacturer of Active...
Logo 400x400.jpg
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
August 31, 2023 07:00 ET | CytoSorbents
PRINCETON, N.J., Aug. 31, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat...
Logo DIPHARMA.jpg
Dipharma receives GMP certification from Brazilian ANVISA
December 01, 2022 08:46 ET | Dipharma Francis S.R.L
MILAN, Italy, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Dipharma Francis S.r.l. (Dipharma), a leading Contract Development and Manufacturing Organization (CDMO) and a global manufacturer of Active...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Receives Brazilian Health Regulatory Agency (ANVISA) Approval for COVISTIX™ (COVID-19 Virus Antigen Detection Test) for Brazil
November 03, 2021 10:06 ET | Sorrento Therapeutics, Inc.
COVISTIX now approved for point of care use in symptomatic patients by ANVISA (national agency for approval of food, cosmetics, and medical devices) in Brazil.Commercialization in progress with...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of 3Q21
June 22, 2021 09:00 ET | Sorrento Therapeutics, Inc.
Phase 2 US clinical trial of Abivertinib randomized last patient (#96) on 4/07/2021.Phase 2 Brazilian clinical trial of Abivertinib randomized last patient (#400) on 06/20/2021.Studies are...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Pivotal Clinical Trial of COVI-MSC™ in Hospitalized COVID-19 Patients With Acute Respiratory Distress Syndrome
May 20, 2021 09:00 ET | Sorrento Therapeutics, Inc.
Brazil Phase 2 Pivotal clinical trial of COVI-MSC is now authorized to proceed.The study will compare therapy using mesenchymal stem cells to placebo (and standard of care) in 100 COVID-19 patients...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Therapeutics’ Large Phase 2 Clinical Trial of Abivertinib in Mild, Moderate and Severe COVID-19 Patients
October 14, 2020 11:57 ET | Sorrento Therapeutics, Inc.
Phase 2 clinical trials of Abivertinib now cleared to proceed in both Brazil and the U.S.Studies are complementary and address both dose duration and disease stageRapid enrollment expected for both...
logo.jpg
Earth Science Tech, Inc. Shares Progress on its Cannabis (CBD) Patent Formulas
July 10, 2018 08:35 ET | Earth Science Tech, Inc.
DORAL, Florida, July 10, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and...